BRAIN ACCESS Trademark
BRAIN ACCESS is a USPTO trademark filed by Braizon Therapeutics, Inc.. Status: Registered.
Trademark Facts
| Mark | BRAIN ACCESS |
|---|---|
| Serial Number | 90042690 |
| Registration Number | 6945464 |
| Status | Registered |
| Filing Date | 2020-07-08 |
| Registration Date | 2023-01-10 |
| Mark Type | Word |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals), 040 (Material Treatment), 042 (Software & IT) |
| Owner | Braizon Therapeutics, Inc. |
| Attorney of Record | M. SCOTT ALPRIN |
| Prosecution Events | 39 |
| Latest Event | R.PR on 2023-01-10 |
Goods & Services
Class 001: Chemicals, namely, chemicals for in vivo industrial use for analyzing the central nervous system; chemicals used in industry for in vivo analysis of the central nervous system; Class 005: Pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the prevention of central nervous system diseases; pharmaceutical preparations for the prevention of central nervous system disorders; pharmaceutical preparations for the treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the brain for the treatment of central nervous system diseases; pharmaceutical preparations for the brain for the treatment of central nervous system disorders; pharmaceutical preparations for the brain for the prevention of central nervous system diseases; pharmaceutical preparations for the brain for the prevention of central nervous system disorders; pharmaceutical preparations for the brain for treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the brain for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of central nervous system diseases; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of central nervous system disorders; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of central nervous system diseases; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of central nervous system disorders; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; dietary supplements for humans; dietary supplements for animals; in vivo diagnostic agents for medical purposes specifically for analyzing the central nervous system; radio-isotope markers for therapeutic or in vivo diagnostic use; Class 040: Custom manufacture of pharmaceuticals; processing of medicinal materials; Custom manufacture of chemicals, except for chemicals for in vitro diagnostic use; Class 042: Testing, inspection or research of pharmaceuticals, chemicals or cosmetics, except for chemicals for in vitro diagnostic use; testing the functionality of machines, except for machines for in vitro diagnostic use; research on machines, except for machines for in vitro diagnostic use